EyePoint Pharmaceuticals, Inc. (EYPT) News

EyePoint Pharmaceuticals, Inc. (EYPT): $2.39

-0.15 (-6.09%)

POWR Rating

Component Grades













Filter EYPT News Items

EYPT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EYPT News Highlights

  • EYPT's 30 day story count now stands at 12.
  • Over the past 25 days, the trend for EYPT's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • EYE, ACAD and AMD are the most mentioned tickers in articles about EYPT.

Latest EYPT News From Around the Web

Below are the latest news stories about EYEPOINT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate EYPT as an investment opportunity.

EyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

- Positive neuroprotective effect of vorolanib, the active drug in EYP-1901, in a widely validated retinal detachment model demonstrates a potential new mechanism of action for the treatment of retinal disease - - Clinical outcomes from real-world CALM registry study of YUTIQ® demonstrates effective control of inflammation in chronic posterior segment uveitis - WATERTOWN, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing an

Yahoo | March 20, 2023

Strength Seen in Acadia (ACAD): Can Its 5.0% Jump Turn into More Strength?

Acadia (ACAD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Yahoo | March 15, 2023

Down -32.42% in 4 Weeks, Here's Why You Should You Buy the Dip in EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals (EYPT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | March 9, 2023

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2022 Earnings Call Transcript

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2022 Earnings Call Transcript March 2, 2023 Operator: Good day and welcome to the EyePoint Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. . Please be advised […]

Yahoo | March 6, 2023

EyePoint Pharmaceuticals Full Year 2022 Earnings: EPS Misses Expectations

EyePoint Pharmaceuticals ( NASDAQ:EYPT ) Full Year 2022 Results Key Financial Results Revenue: US$41.4m (up 12% from FY...

Yahoo | March 4, 2023

Q4 2022 EyePoint Pharmaceuticals Inc Earnings Call

Q4 2022 EyePoint Pharmaceuticals Inc Earnings Call

Yahoo | March 3, 2023

EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 3.17% and 8.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 2, 2023

EyePoint Pharma Takes $20.7M Intangible Impairment Charge In Q4, Shares Pipeline Update, Expects Cash Runway Into 2024

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has reported Q4 revenues of $10.5 million, down 8.8% Y/Y, almost in line with the consensus of $10.40 million. Non-operating income totaled $0.3 million, and the net loss was $(43.5) million, or ($1.16) per share, compared to a net loss of $(19.4) million, or ($0.59) per share, for the prior year period. Wall Street's estimate was an EPS loss of $(0.61). Net product revenue for Yutiq was $9.0 million, a 55% Y/Y increase, with customer demand of approxi

Yahoo | March 2, 2023

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments

– Phase 2 DAVIO 2 clinical trial in wet AMD on track with topline data anticipated by year-end 2023 – – Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy (NPDR) on track with enrollment completion anticipated in 4Q 2023 – – Net product revenues for Full Year 2022 of $39.9 million, a 13.0% increase versus Full Year 2021 of $35.3 million – – $144.6M of cash and investments at December 31, 2022 with cash runway projected into 2H 2024 – – Management to host a conference call and

Yahoo | March 2, 2023

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences: Cowen 43rd Annual Healthcare ConferenceForum: Fireside ChatDate: Monday, March 6, 2023Time: 9:10 a.m. ET Guggenheim 4th Annual Healthy Altitudes SummitForum: Fireside ChatDate

Yahoo | February 27, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6813 seconds.